[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)].
The aspects of virus hepatitis C immunopathogenesis are discussed. The main attention is paid to higher production of Th1 cytokines providing active protection of the host from HCV. The up-to-date approaches to the therapy of chronic hepatitis C, described in the literature and the original ones, including the triple therapy with immunomodulators of various mechanisms of action, i.e. cycloferon (injections and tablets), galavit and derinat are presented. The comparative efficacy of the therapy is estimated. Cycloferon is shown to be the drug of choice in the treatment of patients with virus hepatitis addicted to narcotics. The clinical and laboratory efficacy of the metabolic hepatoprotector remaxol with antioxidant activity is described. Its high effictivity and satisfactory tolerability (side effects requiring discontinuation of the drug use were recorded only in 0.3% of the cases), as well as the minimal risk of no biochemical remission after its use allow to conseder remaxol as a highly efficient metabolic hepatoprotector for pathogenetic therapy of chronic hepatitis.
Romantsov
M G
MG
Sologub
T V
TV
Goriacheva
L G
LG
Kovalenko
S N
SN
Sukhanov
D S
DS
Shul'diakov
A A
AA
Bondarenko
A N
AN
Kovalenko
A L
AL
Petrov
A Iu
AIu
D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004247:DNA / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000523:psychology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008165:Luminol / Q000031:analogs & derivatives; D008297:Male; D010793:Phthalazines / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
D000166:Acridines; D000975:Antioxidants; D000998:Antiviral Agents; C541364:Derinat; D007155:Immunologic Factors; D016898:Interferon-alpha; D010793:Phthalazines; C555877:Remaxol; D013386:Succinates; D012254:Ribavirin; D008165:Luminol; D004247:DNA; C511308:sodium luminolate; C026430:10-carboxymethyl-9-acridanone